The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Brain disease patients with a year to live could choose assisted dying under plans to be considered by MPs next week ...
The trial will assess the efficacy and safety of the system in individuals with movement disorders such as Parkinson's disease.
MPs and campaigners say that people suffering from Motor Neurone Disease or Parkinson’s should have greater access to an ...
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback